Carperitide | CAS# 89213-87-6 | Decompensated Congestive Heart Failure

MedKoo Cat#: 412395 | Name: Carperitide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Carperitide, also known as SUN4936 and Atrial Natriuretic Peptide (1-28) (human) (trifluoroacetate salt), is an endogenous peptide generated by proteolysis of prepro-ANP that is secreted by cardiomyocytes in the heart. It has effects on the renal and cardiovascular systems that decrease vasoconstriction, inhibit renin secretion, and increase sodium excretion. Human Atrial Natriuretic Peptide (ANP) binds to ANP receptors on cultured vascular smooth muscle cells (VSMCs) with a Kd value of approximately 1-2 nM and increases cGMP levels in a dose-dependent manner.

Chemical Structure

Carperitide

CAS#89213-87-6 (free base)

Theoretical Analysis

MedKoo Cat#: 412395

Name: Carperitide

CAS#: 89213-87-6 (free base)

Chemical Formula: C129H204F3N45O41S3

Exact Mass: 3078.4447

Molecular Weight: 3194.50

Elemental Analysis: C, 48.50; H, 6.44; F, 1.78; N, 19.73; O, 20.53; S, 3.01

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 700.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

89213-87-6 (free base)

Synonym

Carperitide; SUN4936; SUN-4936; SUN 4936;Atrial Natriuretic Peptide (1-28) (human) (trifluoroacetate salt); ANF; ANP; Atrial Natriuretic Factor; α-Atriopeptin (human);

IUPAC/Chemical Name

((4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-amino-3-hydroxypropanamido)-4-methylpentanamido)-5-guanidinopentanamido)-5-guanidinopentanamido)-3-hydroxypropanamido)-3-hydroxypropanamido)-19-(3-amino-3-oxopropyl)-49-benzyl-28-((S)-sec-butyl)-34-(carboxymethyl)-31,40-bis(3-guanidinopropyl)-16-(hydroxymethyl)-10-isobutyl-22-methyl-37-(2-(methylthio)ethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane-4-carbonyl)-L-asparaginyl-L-seryl-L-phenylalanyl-L-arginyl-L-tyrosine compound with 2,2,2-trifluoroacetic acid (1:1)

InChi Key

KRPBFBHGALSBQB-SYGLLGJNSA-N

InChi Code

InChI=1S/C127H203N45O39S3.C2HF3O2/c1-9-64(6)99-121(209)150-52-94(182)151-65(7)100(188)155-76(34-35-91(129)179)109(197)167-85(56-174)104(192)149-53-96(184)153-78(43-62(2)3)102(190)148-54-97(185)154-89(119(207)164-82(48-92(130)180)114(202)169-86(57-175)116(204)163-81(46-67-23-14-11-15-24-67)113(201)158-73(27-18-39-143-125(135)136)107(195)166-84(122(210)211)47-68-30-32-69(178)33-31-68)60-213-214-61-90(171-118(206)88(59-177)170-117(205)87(58-176)168-108(196)74(28-19-40-144-126(137)138)156-106(194)72(26-17-38-142-124(133)134)157-112(200)79(44-63(4)5)161-101(189)70(128)55-173)120(208)162-80(45-66-21-12-10-13-22-66)103(191)147-50-93(181)146-51-95(183)152-71(25-16-37-141-123(131)132)105(193)160-77(36-42-212-8)110(198)165-83(49-98(186)187)115(203)159-75(111(199)172-99)29-20-41-145-127(139)140;3-2(4,5)1(6)7/h10-15,21-24,30-33,62-65,70-90,99,173-178H,9,16-20,25-29,34-61,128H2,1-8H3,(H2,129,179)(H2,130,180)(H,146,181)(H,147,191)(H,148,190)(H,149,192)(H,150,209)(H,151,182)(H,152,183)(H,153,184)(H,154,185)(H,155,188)(H,156,194)(H,157,200)(H,158,201)(H,159,203)(H,160,193)(H,161,189)(H,162,208)(H,163,204)(H,164,207)(H,165,198)(H,166,195)(H,167,197)(H,168,196)(H,169,202)(H,170,205)(H,171,206)(H,172,199)(H,186,187)(H,210,211)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)(H4,137,138,144)(H4,139,140,145);(H,6,7)/t64-,65-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,99-;/m0./s1

SMILES Code

[H]N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N[C@H](C(N[C@@H](CCCNC(N)=N)C(N[C@]([C@H](CC)C)([H])C(NCC(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CO)C(NCC(N[C@@H](CC(C)C)C(NCC1=O)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)CC(O)=O)=O)CCSC)=O)=O)=O)=O)CC2=CC=CC=C2)=O)CSSC[C@H](N1)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@H](C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(O)=O)CC3=CC=C(O)C=C3)=O)=O)CC4=CC=CC=C4)=O)=O)=O)=O)=O)=O)=O)=O)=O.FC(F)(C(O)=O)F

Appearance

Solid powder

Purity

>96% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Sequence (3-letter): Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH [Cys7-Cys23] Sequence (1-letter): SLRRSSCFGGRMDRIGAQSGLGCNSFRY-OH

Certificate of Analysis

View CoA: current batch, Lot#E23C03B06

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 3,194.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Suzuki S, Aoki Y, Anezaki H, Wakuda C, Oshima S, Nishimoto H, Kobayashi A, Kato H, Doi M, Nakajima Y. Association Between the Presence of Pulmonary Hypertension Before Cardiovascular Surgery and the Nephroprotective Effect of Carperitide: A Retrospective Cohort Study. Cureus. 2022 Mar 6;14(3):e22891. doi: 10.7759/cureus.22891. PMID: 35399394; PMCID: PMC8982997. 2: Nogi K, Ueda T, Matsue Y, Nogi M, Ishihara S, Nakada Y, Kawakami R, Kagiyama N, Kitai T, Oishi S, Akiyama E, Suzuki S, Yamamoto M, Kida K, Okumura T, Saito Y. Effect of carperitide on the 1 year prognosis of patients with acute decompensated heart failure. ESC Heart Fail. 2022 Apr;9(2):1061-1070. doi: 10.1002/ehf2.13770. Epub 2022 Feb 4. PMID: 35118813; PMCID: PMC8934945. 3: Kamiya M, Sato N, Shimizu W. Therapeutic strategy using low-dose carperitide in patients with acute heart failure. Heart Vessels. 2020 Dec;35(12):1767-1768. doi: 10.1007/s00380-020-01636-7. Epub 2020 Jul 21. PMID: 32696133. 4: Imamura T. Therapeutic strategy using low-dose carperitide monotherapy in patients with acute heart failure. Heart Vessels. 2020 Dec;35(12):1766. doi: 10.1007/s00380-020-01635-8. Epub 2020 May 29. PMID: 32472228. 5: Kamiya M, Sato N, Matsuda J, Nozaki A, Akiya M, Sato T, Okazaki H, Takahashi Y, Shimizu W. Predictors of responders for low-dose carperitide monotherapy in patients with acute heart failure. Heart Vessels. 2020 Jan;35(1):59-68. doi: 10.1007/s00380-019-01450-w. Epub 2019 Jun 21. PMID: 31227874. 6: Nagai T, Iwakami N, Nakai M, Nishimura K, Sumita Y, Mizuno A, Tsutsui H, Ogawa H, Anzai T; JROAD-DPC investigators. Effect of intravenous carperitide versus nitrates as first-line vasodilators on in-hospital outcomes in hospitalized patients with acute heart failure: Insight from a nationwide claim- based database. Int J Cardiol. 2019 Apr 1;280:104-109. doi: 10.1016/j.ijcard.2019.01.049. Epub 2019 Jan 15. PMID: 30674432. 7: Okuhara Y, Asakura M, Azuma K, Orihara Y, Nishimura K, Ando T, Kondo H, Naito Y, Kashiwase K, Hirotani S, Ishihara M, Masuyama T. Effects of early diuretic response to carperitide in acute decompensated heart failure treatment: A single-center retrospective study. PLoS One. 2018 Jun 18;13(6):e0199263. doi: 10.1371/journal.pone.0199263. PMID: 29912952; PMCID: PMC6005462. 8: Kawase Y, Hata R, Tada T, Katoh H, Kadota K. Effects of Carperitide on Degree of Pulmonary Congestion in Treatment of Acute Heart Failure. Circ J. 2018 Jul 25;82(8):2079-2088. doi: 10.1253/circj.CJ-18-0057. Epub 2018 May 24. PMID: 29794402. 9: Nagai T, Honda Y, Nakano H, Honda S, Iwakami N, Mizuno A, Komiyama N, Yamane T, Furukawa Y, Miyagi T, Nishihara S, Tanaka N, Adachi T, Hamasaki T, Asaumi Y, Tahara Y, Aiba T, Sugano Y, Kanzaki H, Noguchi T, Kusano K, Yasuda S, Ogawa H, Anzai T. Rationale and Design of Low-dose Administration of Carperitide for Acute Heart Failure (LASCAR-AHF). Cardiovasc Drugs Ther. 2017 Dec;31(5-6):551-557. doi: 10.1007/s10557-017-6760-z. PMID: 29098501. 10: Koeda C, Yamaya S, Hozawa M, Sato M, Nasu K, Takahashi T, Terui K. Comparison of the Effects of Carperitide and Tolvaptan on Patients with Left Ventricular Dysfunction: A Two-Center Retrospective Study. Cardiol Res Pract. 2017;2017:6935342. doi: 10.1155/2017/6935342. Epub 2017 Jul 12. PMID: 28785506; PMCID: PMC5529620. 11: Mizuno A, Iguchi H, Sawada Y, Hurley M, Nomura H, Hayashi K, Tokuda Y, Watanabe S, Yoshikawa A. The impact of carperitide usage on the cost of hospitalization and outcome in patients with acute heart failure: High value care vs. low value care campaign in Japan. Int J Cardiol. 2017 Aug 15;241:243-248. doi: 10.1016/j.ijcard.2017.04.078. Epub 2017 Apr 26. PMID: 28476514. 12: Ogiso M, Isogai T, Okabe Y, Ito K, Tsuji M, Tanaka H. Effect of carperitide on in-hospital mortality of patients admitted for heart failure: propensity score analyses. Heart Vessels. 2017 Aug;32(8):916-925. doi: 10.1007/s00380-017-0952-0. Epub 2017 Feb 20. PMID: 28220240. 13: Tsukamoto M, Koyama S, Esaki K, Hitosugi T, Yokoyama T. Low-dose carperitide (α-human A-type natriuretic peptide) alleviates hemoglobin concentration decrease during prolonged oral surgery: a randomized controlled study. J Anesth. 2017 Jun;31(3):325-329. doi: 10.1007/s00540-017-2309-3. Epub 2017 Jan 30. PMID: 28138765. 14: Okuhara Y, Hirotani S, Ando T, Nishimura K, Orihara Y, Komamura K, Naito Y, Mano T, Masuyama T. Comparison of salt with low-dose furosemide and carperitide for treating acute decompensated heart failure: a single-center retrospective cohort study. Heart Vessels. 2017 Apr;32(4):419-427. doi: 10.1007/s00380-016-0883-1. Epub 2016 Jul 28. PMID: 27469321. 15: Sezai A, Osaka S, Yaoita H, Ishii Y, Arimoto M, Hata H, Shiono M. Efficacy of Carperitide in Hemodialysis Patients Undergoing Cardiac Surgery. Ann Thorac Cardiovasc Surg. 2016 Aug 23;22(4):237-45. doi: 10.5761/atcs.oa.15-00239. Epub 2016 Mar 30. PMID: 27025780; PMCID: PMC5045851. 16: Kawase Y, Kadota K, Tada T, Hata R, Iwasaki K, Maruo T, Katoh H, Mitsudo K. Predictors of Worsening Renal Function in Patients With Acute Decompensated Heart Failure Treated by Low-Dose Carperitide. Circ J. 2016;80(2):418-25. doi: 10.1253/circj.CJ-15-0928. Epub 2015 Dec 15. PMID: 26667591. 17: Sasabuchi Y, Yasunaga H, Matsui H, Lefor AK, Fushimi K, Sanui M. Carperitide Increases the Need for Renal Replacement Therapy After Cardiovascular Surgery. J Cardiothorac Vasc Anesth. 2015 Dec;29(6):1426-31. doi: 10.1053/j.jvca.2015.04.022. Epub 2015 Apr 28. PMID: 26275514. 18: Matsue Y, Kagiyama N, Yoshida K, Kume T, Okura H, Suzuki M, Matsumura A, Yoshida K, Hashimoto Y. Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis. J Card Fail. 2015 Nov;21(11):859-64. doi: 10.1016/j.cardfail.2015.05.007. Epub 2015 May 18. PMID: 25999241. 19: Sezai A, Iida M, Yoshitake I, Wakui S, Osaka S, Kimura H, Yaoita H, Hata H, Shiono M, Nakai T, Takayama T, Kunimoto S, Kasamaki Y, Hirayama A. Carperitide and atrial fibrillation after coronary bypass grafting: the Nihon University working group study of low-dose HANP infusion therapy during cardiac surgery trial for postoperative atrial fibrillation. Circ Arrhythm Electrophysiol. 2015 Jun;8(3):546-53. doi: 10.1161/CIRCEP.113.001211. Epub 2015 Apr 3. PMID: 25840580. 20: Asanuma H, Sanada S, Asakura M, Asano Y, Kim J, Shinozaki Y, Mori H, Minamino T, Takashima S, Kitakaze M. Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: role of NO. Hypertens Res. 2014 Aug;37(8):716-23. doi: 10.1038/hr.2014.70. Epub 2014 Apr 3. PMID: 24694647.